The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy

128Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cancer immunotherapy has recently shown promising antitumor effects in various types of tumors. Among all immune checkpoints, the PD-1/PD-L1 pathway plays an important role in the immune evasion of tumor cells, making it a potent target in antitumor immunity. Accordingly, antibodies targeting the PD-1/PD-L1 pathway have been developed to attack tumor cells; however, resistance to immune therapy remains to be solved. Hence, identification of the underlying modulators of the PD-1/PD-L1 pathway is of significant importance to understand the mechanisms of antitumor immunotherapy. Long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) have been identified to regulate the PD-1/PD-L1 pathway, leading to participation in the immune response and immunotherapy. Therefore, this review focuses on the functions of lncRNAs and circRNAs in regulation of the PD-1/PD-L1 axis in tumorigenesis and tumor progression. We hope this review will stimulate research to supply more precise and effective cancer immune checkpoint therapies for a large number of tumors.

Cite

CITATION STYLE

APA

Jiang, W., Pan, S., Chen, X., Wang, Z. wei, & Zhu, X. (2021, December 1). The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy. Molecular Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12943-021-01406-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free